Stock listing

NASDAQ:DMRA Damora Therapeutics, Inc. Stock

Home listing (NASDAQ) of Damora Therapeutics, Inc.

Follow Damora Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:DMRA

$23.22 USD +0.24 (+1.0%)

Close on Nov 20, 2026

Past year +33.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$23.13 – $24.51 USDNov 20, 2026
Volume
643,377 sharesNov 20, 2026
Market cap
$1.44B USDAt the close on Nov 20, 2026 · price × 61.90M shares outstanding
52-week range
$15.76 – $38.33 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$13.12M USDMedian day 473,165 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Damora Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:DMRA · Home$23.22 USD+0.24 (+1.0%)643,377$23.81$24.51$23.13$22.98Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:DMRA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$23.22+0.24+1.0%$23.81$24.51$23.13643,377
$22.98+0.42+1.9%$22.54$23.61$22.08580,492
$22.56+0.065+0.3%$22.65$22.75$21.89395,993
$22.50+0.895+4.1%$21.88$23.75$21.331,232,435
$21.60-0.45-2.0%$22.11$22.38$21.15475,265
$22.05-1.20-5.2%$23.04$23.04$21.83671,091
$23.25-0.90-3.7%$24.15$25.07$23.20535,858
$24.15+0.08+0.3%$23.75$24.76$23.45466,095
$24.07+0.37+1.6%$24.01$24.94$23.34564,142
$23.70+1.84+8.4%$22.01$24.16$21.13360,452
$21.86-1.08-4.7%$23.15$24.80$20.75792,593
$22.94+0.86+3.9%$23.37$23.40$21.45736,739
$22.08+0.48+2.2%$21.76$22.77$21.70473,165
$21.60+0.11+0.5%$21.75$21.94$20.75497,323
$21.49-0.52-2.4%$21.95$22.20$21.05339,515
$22.01+0.40+1.9%$22.06$23.21$21.50460,310
$21.61-0.35-1.6%$21.93$22.51$20.46341,763
$21.96+0.70+3.3%$21.26$22.27$20.23286,092
$21.26+0.17+0.8%$21.19$21.78$21.09641,718
$21.09-0.62-2.9%$21.40$21.53$20.46359,783
$21.71+0.18+0.8%$21.45$21.88$20.92420,641
$21.53+0.86+4.2%$20.88$22.68$20.66683,090
$20.67+1.40+7.3%$19.30$20.92$19.30242,321
$19.27+0.83+4.5%$18.56$19.94$18.52293,164
$18.44-0.30-1.6%$18.69$18.80$17.49836,700
$18.74+0.31+1.7%$18.59$18.89$17.84357,600
$18.43-0.13-0.7%$18.21$18.98$18.00277,600
$18.56-1.695-8.4%$20.09$20.28$18.50285,200
$20.26-0.825-3.9%$20.93$21.26$20.05267,900
$21.08+0.52+2.5%$20.53$21.86$20.44368,700
$20.56+0.32+1.6%$19.96$20.87$19.22341,800
$20.24+0.69+3.5%$19.36$20.35$18.69488,800
$19.55-0.67-3.3%$20.42$20.48$18.201,171,600
$20.22-0.43-2.1%$20.64$20.70$19.54556,100
$20.65+0.42+2.1%$20.55$20.77$19.59692,900
$20.23-1.05-4.9%$20.51$21.25$20.20354,600
$21.28+0.62+3.0%$20.78$21.85$20.31563,000
$20.66-0.09-0.4%$20.67$20.82$20.16376,400
$20.75+0.09+0.4%$21.26$21.59$19.83514,900
$20.66+0.39+1.9%$20.80$20.80$19.801,431,800
$20.27-0.17-0.8%$20.38$20.73$19.39875,200
$20.44-1.97-8.8%$22.12$22.12$19.961,067,200
$22.41-0.44-1.9%$23.21$23.43$21.95355,200
$22.85+0.26+1.2%$22.80$23.33$22.01618,200
$22.59-0.19-0.8%$22.94$23.44$22.023,316,800
$22.78-1.75-7.1%$24.96$25.49$22.74605,100
$24.53-0.22-0.9%$24.88$25.27$23.911,241,800
$24.75-3.64-12.8%$28.00$28.17$24.141,677,900
$28.39+0.29+1.0%$28.42$29.18$28.00372,100
$28.10+1.26+4.7%$27.32$28.53$26.87525,400
$26.84+0.57+2.2%$25.87$27.78$25.63639,800
$26.27-2.90-9.9%$28.77$29.29$26.26500,100
$29.17-0.89-3.0%$29.66$30.74$28.89560,000
$30.06+2.06+7.4%$27.49$30.35$27.39295,800
$28.00-0.18-0.6%$28.52$28.60$27.40328,200
$28.18+0.04+0.1%$28.36$29.38$27.82462,900
$28.14-0.04-0.1%$28.10$28.45$27.12272,700
$28.18-0.82-2.8%$28.93$28.93$26.53497,000
$29.00-1.60-5.2%$30.38$30.71$28.42371,700
$30.60+0.21+0.7%$30.18$31.11$29.87171,300
$30.39-0.23-0.8%$30.48$30.88$30.10185,900
$30.62+0.31+1.0%$30.55$31.64$30.54205,709
$30.31-0.51-1.7%$30.67$31.49$29.70319,817
$30.82+0.51+1.7%$30.45$31.38$30.15159,900
$30.31-2.13-6.6%$31.84$32.07$30.12226,500

Splits

1 split · NASDAQ:DMRA · every price before a split is adjusted for it

DayRatioWhat
1-for-25Consolidation
Ticker
NASDAQ:DMRA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Damora Therapeutics, Inc. news

Damora Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
13 in the last 12 months · 13 in all · newest Nov 5, 2026 · oldest 2026
Decks
2 decks · latest August 2026

Where Damora Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:DMRA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:DMRABOATSUnited StatesUSD

Valuation

Price/book 2.9× against a median of 2.5×: 6th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$910.0M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.9×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.88

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Damora Therapeutics, Inc. · NASDAQ:DMRAUS$1.44BUS$910.0Mn/an/an/a2.9×n/a0.0×0.88
Alvotech · NASDAQ:ALVOUS$1.47BUS$2.78Bn/a5.7×31.4×n/a−36.5%n/a0.90
ABL Bio, Inc. · KRX:298380US$1.47BUS$1.34Bn/a52.7×n/a11.5×−229.4%0.0×n/a
Mesoblast Limited · ASX:MSBUS$1.46BUS$1.42Bn/a82.5×n/a2.4×−593.9%0.2×n/a
PELL Bio-Med Technology Co Ltd · TWSE:6949US$1.46BUS$1.40Bn/a1,591×n/a18.7×n/a0.1×n/a
Vir Biotechnology, Inc. · NASDAQ:VIRUS$1.44BUS$1.07Bn/a3.5×n/a1.6×−61.0%0.1×1.82
Voronoi, Inc. · KRX:310210US$1.44BUS$1.39Bn/an/an/a27.9×n/a0.5×n/a
Kailera Therapeutics, Inc. · NASDAQ:KLRAUS$1.43BUS$539.5Mn/an/an/a1.4×n/a0.0×1.28
Sarepta Therapeutics, Inc. · NASDAQ:SRPTUS$1.43BUS$1.41Bn/a0.7×n/a0.9×−5.9%0.6×1.70
LigaChem Biosciences Inc. · KRX:141080US$1.42BUS$1.14Bn/a15.5×n/a4.8×−180.9%0.0×n/a
ADARx Pharmaceuticals, Inc. · NASDAQ:ADRXUS$1.42BUS$521.8Mn/a77.6×n/a2.5×n/a0.0×n/a
Median of the othersUS$1.44BUS$1.37B34.1×31.4×2.5×−121.0%0.1×1.49

Forecasts

9 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
46.78 USD · Analysts' mean
EPS, year to Dec 2026
-1.89 · 4 analysts

Team and board

Officers

OfficerRole
Jennifer JarrettPresident and Chief Executive Officer in March 2026, Board Director
Brian BurkavageSenior Vice President, Finance
Sherwin SattarzadehChief Operating Officer
Garrett WinslowGeneral Counsel
Becker HewesChief Medical Officer
Jim BakerChief Corporate Affairs Officer

Board

DirectorRole
Peter HarwinChairman of the Board
Andrew ChengBoard Director
Cameron TurtleBoard Director
Chris CainBoard Director
Jennifer JarrettPresident and Chief Executive Officer in March 2026, Board Director
Julianne BrunoBoard Director
Michael LandsittelBoard Director

Events

QuarterResultsShare move
Q3 2026Nov 4, 2026 · After close−4.7%
Q2 2026Aug 10, 2026 · After close+2.8%
Q1 2026May 13, 2026+3.4%
Q4 2025Mar 20, 2026+20.1%
Q3 2025Nov 7, 2025+196.4%
Q2 2025Aug 6, 2025−4.1%
Q1 2025May 9, 2025−2.5%
Q4 2024Mar 19, 2025 · After close−2.1%
Q3 2024Nov 1, 2024 · Before open−1.5%
Q2 2024Aug 12, 2024 · After close+6.3%
All 20 quarters
QuarterResultsShare move
Q1 2024Apr 29, 2024 · After close−3.7%
Q4 2023Mar 25, 2024−3.7%
Q3 2023Nov 6, 2023 · After close+7.4%
Q2 2023Jul 31, 2023 · After close−9.1%
Q1 2023Apr 28, 2023−4.5%
Q4 2022Mar 9, 2023 · Before open−8.1%
Q3 2022Nov 8, 2022 · Before open−7.3%
Q2 2022Jul 29, 2022 · Before open−3.6%
Q1 2022Apr 29, 20220.0%
Q4 2021Feb 17, 2022 · After close−5.3%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck23 slidesAugust 2026
Investor Presentation (May 2026)Investor deck22 slidesMay 2026

Open Decks

IPO

Went public as Galecto, Inc. Priced at US$15.00 a share on Oct 28, 2020.

Price
US$15.00 a share
Shares offered
5,666,667 shares of common stock
Offering size
US$85 million
Underwriters' option
Up to 850,000 more shares
Underwriters
BofA Securities, SVB Leerink, Kempen & Co, Credit Suisse · In the order on the cover
Shares delivered
On or about Nov 2, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceSep 2, 2020
Filed publiclyOct 7, 2020
Amended onceOct 22, 2020
Shares registered with an exchangeOct 23, 2020
Declared effective by the SECOct 28, 2020
Final prospectus, with the priceOct 30, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Oct 30, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue00000
Cost of revenue34.0K181.0K830.0K490.0K441.0K188.0K111.0K
Gross profit-34.0K-181.0K-830.0K-490.0K-441.0K-188.0K-111.0K
Research and development26.9M6.40M23.8M48.2M38.5M24.6M19.7M10.1M
Selling, general and administrative9.69M10.5M12.7M13.0M13.7M
Operating income-210.9M-22.3M-39.9M-61.2M-52.2M-33.6M39.0M-12.9M
Depreciation and amortization22.0K21.0K269.0K42.0K20.0K188.0K111.0K
EBITDA-210.8M-22.2M-39.6M-61.2M-52.2M-33.4M39.1M
Interest expense2.97M
Income before tax-209.8M-21.4M-38.3M-61.6M-51.8M-34.8M-36.5M-15.9M
Income tax50.0K41.0K00000
Net income-209.8M-21.4M-38.3M-61.6M-51.8M-34.8M-36.5M-15.9M
Earnings per share, basic3.98-18.53-36.08-2.43-2.05-7.62-161.82-15.60
Earnings per share, diluted3.98-18.53-36.08-2.43-2.05-7.62-161.82

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents257.6M14.2M21.5M32.8M62.6M163.6M11.3M31.0M
Short-term investments0011.7M27.4M37.6M
Receivables899.0K881.0K1.72M1.38M2.28M2.21M41.1M989.0K
Current assets260.4M16.8M36.8M63.9M110.1M169.3M56.1M35.0M
Property, plant and equipment36.0K57.0K78.0K357.0K203.0K
Total assets260.5M17.1M38.2M73.2M122.2M171.6M56.6M35.1M
Accounts payable444.0K377.0K1.70M3.35M1.53M2.85M3.33M1.41M
Current liabilities20.1M1.20M5.83M11.1M4.54M5.57M7.93M4.44M
Total debt68.0K1.43M249.0K804.0K847.0K915.0K298.0K
Total liabilities20.1M1.30M5.90M11.4M4.99M6.11M8.14M4.44M
Shareholders' equity239.0M14.5M32.3M61.8M117.2M165.5M-71.1M30.7M
Shares outstanding1.60M1.32M1.08M25.7M25.3M25.3M260.0K1.02M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-6.73M-18.6M-36.9M-42.9M-52.3M-38.2M-19.3M-13.7M
Capital spending000-196.0K-223.0K000
Free cash flow-6.73M-18.6M-36.9M-43.1M-52.5M-38.2M-19.3M-13.7M
Cash from investing-17.4M11.7M22.3M12.4M-48.0M-326.0K
Cash from financing266.8M02.88M507.0K0187.4M42.9M
Change in cash242.7M-6.97M-11.7M-30.0M-100.4M149.2M-19.7M31.0M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
4 · Change in ownershipSep 28, 2026Insider tradeSEC
4 · Change in ownershipAug 13, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 13, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveAug 13, 2026Other filingsSEC
S-8 POSAug 10, 2026Offer documentSEC
S-8 POSAug 10, 2026Offer documentSEC
POSASRAug 10, 2026Other filingsSEC
S-8 POSAug 10, 2026Offer documentSEC
S-8 POSAug 10, 2026Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
S-8 POSAug 10, 2026Offer documentSEC
S-8 POSAug 10, 2026Offer documentSEC
S-8 POSAug 10, 2026Offer documentSEC
S-8 POSAug 10, 2026Offer documentSEC
POS AM · Amendment to an effective registrationAug 10, 2026Offer documentSEC
8-A12B/A · Registration of shares for listing on an exchange, amendedAug 10, 2026Other filingsSEC
10-Q · Quarterly reportAug 10, 2026Quarterly reportSEC
144 · Notice of proposed saleAug 6, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeJul 28, 2026Big-stake noticeSEC
8-K · Current reportJul 20, 2026Material contractSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
144 · Notice of proposed saleJun 22, 2026Other filingsSEC
8-K · Current reportJun 17, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
3 · Initial statement of ownershipMay 8, 2026Insider tradeSEC
8-K · Current reportMay 4, 2026Management or board changeSEC
ARS · Annual report to shareholdersMay 1, 2026Annual reportSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
DEFA14A · Additional proxy materialApr 29, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 23, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 23, 2026Big-stake noticeSEC
8-K · Current reportApr 20, 2026Current reportSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 25, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 25, 2026Insider tradeSEC
8-K · Current reportMar 23, 2026Management or board changeSEC
S-8 · Registration statement for employee plansMar 20, 2026Offer documentSEC
10-K · Annual reportMar 19, 2026Annual reportSEC
8-K · Current reportMar 10, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 6, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 11, 2026Big-stake noticeSEC
8-K · Current reportFeb 11, 2026Material contractSEC
424B5 · ProspectusFeb 11, 2026Offer documentSEC
424B5 · ProspectusFeb 10, 2026Offer documentSEC
S-3ASR · Registration statementFeb 10, 2026Offer documentSEC
8-K · Current reportFeb 10, 2026Management or board changeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 26, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 12, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 12, 2026Big-stake noticeSEC
8-K · Current reportJan 12, 2026Current reportSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
8-K · Current reportJan 6, 2026Management or board changeSEC
S-8 · Registration statement for employee plansJan 2, 2026Offer documentSEC
DEF 14A · Proxy statementDec 31, 2025Meeting noticeSEC
424B3 · ProspectusDec 31, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 29, 2025Other filingsSEC
CORRESP · Letter to the SECDec 22, 2025Other filingsSEC
PRE 14A · Preliminary proxy statementDec 16, 2025Meeting noticeSEC
S-3 · Registration statementDec 16, 2025Offer documentSEC
8-K/A · Current report, amendedDec 9, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeDec 5, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeDec 5, 2025Big-stake noticeSEC
DNov 21, 2025Other filingsSEC
3 · Initial statement of ownershipNov 17, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 17, 2025Insider tradeSEC
SCHEDULE 13D · Big-stake noticeNov 17, 2025Big-stake noticeSEC
3 · Initial statement of ownershipNov 17, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 13, 2025Big-stake noticeSEC
8-K · Current reportNov 10, 2025Acquisition or disposalSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 9, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 25, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 5, 2025Quarterly reportSEC
4 · Change in ownershipJul 8, 2025Insider tradeSEC
4 · Change in ownershipJul 8, 2025Insider tradeSEC
4 · Change in ownershipJul 8, 2025Insider tradeSEC
8-K · Current reportJun 20, 2025Meeting outcomeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
ARS · Annual report to shareholdersApr 30, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 30, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 17, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansMar 19, 2025Offer documentSEC
10-K · Annual reportMar 19, 2025Annual reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 16, 2025Big-stake noticeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 7, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 7, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 1, 2024Quarterly reportSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 15, 2024Insider tradeSEC
8-K · Current reportOct 15, 2024Management or board changeSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 11, 2024Insider tradeSEC
8-K · Current reportOct 7, 2024Acquisition or disposalSEC
8-K · Current reportSep 18, 2024Current reportSEC
8-K · Current reportSep 11, 2024Current reportSEC
8-K · Current reportSep 5, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedAug 29, 2024Big-stake noticeSEC
3 · Initial statement of ownershipAug 16, 2024Insider tradeSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
SC 13D/A · Big-stake notice, amendedJun 24, 2024Big-stake noticeSEC
8-K · Current reportJun 21, 2024Meeting outcomeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
10-Q · Quarterly reportApr 29, 2024Quarterly reportSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 16, 2024Meeting noticeSEC
8-K · Current reportMar 26, 2024Current reportSEC
S-8 · Registration statement for employee plansMar 8, 2024Offer documentSEC
10-K · Annual reportMar 8, 2024Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
8-K · Current reportDec 21, 2023Current reportSEC
10-Q · Quarterly reportNov 6, 2023Quarterly reportSEC
8-K · Current reportOct 23, 2023Current reportSEC
SC 13G · Big-stake noticeOct 3, 2023Big-stake noticeSEC
144 · Notice of proposed saleOct 2, 2023Other filingsSEC
144 · Notice of proposed saleOct 2, 2023Other filingsSEC
144 · Notice of proposed saleOct 2, 2023Other filingsSEC
144 · Notice of proposed saleOct 2, 2023Other filingsSEC
8-K · Current reportOct 2, 2023Current reportSEC
8-K · Current reportSep 26, 2023Management or board changeSEC
SC 13D/A · Big-stake notice, amendedSep 18, 2023Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedSep 5, 2023Big-stake noticeSEC
144 · Notice of proposed saleAug 30, 2023Other filingsSEC
144 · Notice of proposed saleAug 30, 2023Other filingsSEC
144 · Notice of proposed saleAug 30, 2023Other filingsSEC
144 · Notice of proposed saleAug 30, 2023Other filingsSEC
144/A · Notice of proposed sale, amendedAug 21, 2023Other filingsSEC
144 · Notice of proposed saleAug 21, 2023Other filingsSEC
144 · Notice of proposed saleAug 21, 2023Other filingsSEC
144 · Notice of proposed saleAug 21, 2023Other filingsSEC
144 · Notice of proposed saleAug 21, 2023Other filingsSEC
4 · Change in ownershipAug 17, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedAug 17, 2023Big-stake noticeSEC
144 · Notice of proposed saleAug 15, 2023Other filingsSEC
144 · Notice of proposed saleAug 15, 2023Other filingsSEC
144 · Notice of proposed saleAug 15, 2023Other filingsSEC
144 · Notice of proposed saleAug 15, 2023Other filingsSEC
8-K · Current reportAug 15, 2023Current reportSEC
4 · Change in ownershipAug 2, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedAug 2, 2023Big-stake noticeSEC
144 · Notice of proposed saleJul 31, 2023Other filingsSEC
144 · Notice of proposed saleJul 31, 2023Other filingsSEC
144 · Notice of proposed saleJul 31, 2023Other filingsSEC
144 · Notice of proposed saleJul 31, 2023Other filingsSEC
10-Q · Quarterly reportJul 31, 2023Quarterly reportSEC
4 · Change in ownershipJul 27, 2023Insider tradeSEC
144 · Notice of proposed saleJul 25, 2023Other filingsSEC
144 · Notice of proposed saleJul 25, 2023Other filingsSEC
144 · Notice of proposed saleJul 25, 2023Other filingsSEC
144 · Notice of proposed saleJul 25, 2023Other filingsSEC
4 · Change in ownershipJul 17, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJul 17, 2023Big-stake noticeSEC
144 · Notice of proposed saleJul 13, 2023Other filingsSEC
144 · Notice of proposed saleJul 13, 2023Other filingsSEC
144 · Notice of proposed saleJul 13, 2023Other filingsSEC
144 · Notice of proposed saleJul 13, 2023Other filingsSEC
8-K · Current reportJun 15, 2023Meeting outcomeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC
4 · Change in ownershipJun 15, 2023Insider tradeSEC

This page holds 200 of 353 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Damora Therapeutics, Inc.’s releases · as of Nov 2, 2026

Common shares
61,904,742
Fully diluted
61,904,742

Fully diluted

LineSharesAs of
Common shares61,904,742Nov 2, 2026

Share count over time

CountShares
Nov 2, 202661,904,742

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Fcpm III Services B.V.2.44M3.9%US$51.9MNo changeNov 16, 2026
a16z Capital Management, L.L.C.1.24M2.0%US$26.3MNo changeNov 16, 2026
Ameritas Investment Partners, Inc.4,211<0.01%US$89,610−634Nov 13, 2026
Nisa Investment Advisors, LLC140<0.01%US$2,979+20Oct 20, 2026

Funds

HolderSharesOf the companyValueChangeAs of
Fidelity Growth Company Fund1.83M3.0%US$45.5M+70,235May 31, 2026
iShares Russell 2000 ETF1.36M2.2%US$35.3MNewJun 30, 2026
JPMorgan Small Cap Growth Fund741K1.2%US$19.3MNewJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF715K1.2%US$18.6M+621KJun 30, 2026
Fidelity Growth Company K6 Fund535K0.86%US$13.3M+13,466May 31, 2026
Select Health Care Portfolio500K0.81%US$12.4MNo changeMay 31, 2026
Select Biotechnology Portfolio455K0.73%US$11.3MNo changeMay 31, 2026
Fidelity Series Growth Company Fund453K0.73%US$11.3M+18,067May 31, 2026
iShares Russell 2000 Growth ETF339K0.55%US$8.82MNewJun 30, 2026
JPMorgan Small Cap Blend Fund238K0.39%US$6.2MNewJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueChangeAs of
Vanguard Extended Market Index Fund213K0.34%US$5.53M+10,923Jun 30, 2026
iShares Russell 2000 Value ETF154K0.25%US$4.01MNewJun 30, 2026
VIP Health Care Portfolio118K0.19%US$3.07MNo changeJun 30, 2026
VIP Contrafund Portfolio106K0.17%US$2.74MNo changeJun 30, 2026
Master Small Cap Index Series95,1340.15%US$2.47MNewJun 30, 2026
Fidelity Extended Market Index Fund93,4640.15%US$2.33M+10,889May 31, 2026
Multi-Manager Small Cap Equity Strategies Fund78,8330.13%US$1.96MNewMay 31, 2026
EQ/2000 Managed Volatility Portfolio57,6710.09%US$1.5MNewJun 30, 2026
LVIP State Street Small-Cap Index Fund37,9000.06%US$986KNewJun 30, 2026
Fidelity Nasdaq Composite Index Fund36,6830.06%US$913KNewMay 31, 2026
Fidelity Small Cap Growth Index Fund34,4420.06%US$896KNewJun 30, 2026
Fidelity Total Market Index Fund33,6950.05%US$838K+4,179May 31, 2026
EQ/Small Company Index Portfolio31,6400.05%US$823KNewJun 30, 2026
College Retirement Equities Fund - Total Global Stock Account31,5600.05%US$821KNewJun 30, 2026
Fidelity Series Total Market Index Fund27,5100.04%US$684K+4,262May 31, 2026
Small Cap Index Fund26,9620.04%US$701KNewJun 30, 2026
Fidelity Advisor New Insights Fund23,8000.04%US$619KNo changeJun 30, 2026
Fidelity Small Cap Value Index Fund23,2610.04%US$605KNewJun 30, 2026
EQ/AB Small Cap Growth Portfolio19,1700.03%US$499KNewJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio18,2000.03%US$473KNewJun 30, 2026
MetLife Russell 2000 Index Portfolio17,8560.03%US$464KNewJun 30, 2026
ATM Small Cap Managed Volatility Portfolio16,7330.03%US$435KNewJun 30, 2026
Fidelity Nasdaq Composite Index ETF16,4690.03%US$410KNewMay 31, 2026
Small-Cap Index Portfolio15,2780.02%US$397KNewJun 30, 2026
iShares Russell 3000 ETF13,9670.02%US$363KNewJun 30, 2026
Fidelity Series Opportunistic Insights Fund12,8000.02%US$333KNo changeJun 30, 2026
NVIT Small Cap Index Fund11,7900.02%US$307KNewJun 30, 2026
Small Cap Index Trust10,7520.02%US$280KNewJun 30, 2026
DWS Small Cap Index VIP8,1660.01%US$212KNewJun 30, 2026
T. Rowe Price Small-Cap Index Fund8,1430.01%US$212KNewJun 30, 2026
BlackRock Small Cap Index V.I. Fund7,1850.01%US$187KNewJun 30, 2026
Voya RussellTM Small Cap Index Portfolio6,4830.01%US$169KNewJun 30, 2026
Diversified Equity Alpha Master Portfolio6,2230.01%US$162KNewJun 30, 2026
EQ/Morgan Stanley Small Cap Growth Portfolio5,553<0.01%US$144KNewJun 30, 2026
CVT Russell 2000 Small Cap Index Portfolio4,845<0.01%US$126KNewJun 30, 2026
T. Rowe Price Extended Equity Market Index Fund4,323<0.01%US$112KNo changeJun 30, 2026
Venerable Small Cap Index Fund4,262<0.01%US$111KNewJun 30, 2026
Voya VACS Index Series SC Portfolio3,578<0.01%US$93,064NewJun 30, 2026
PD Small-Cap Growth Index Portfolio3,349<0.01%US$87,107NewJun 30, 2026
Profund Vp Biotechnology3,170<0.01%US$82,452+2,648Jun 30, 2026

This page holds 50 of 70 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Jarrett Jennifer
Director, Officer: Director, President and CEO
Buy12,500USD 20.23US$253KSep 25, 2026
Winslow Garrett
Officer: General Counsel
Sale245USD 29.98US$7,345Jul 6, 2026

Big stakes

HolderStakeSharesDate
Fairmount Funds Management LLC19.99%8.71MFeb 9, 2026
FMR LLC15.00%239KNov 28, 2025
Avoro Capital Advisors LLC6.27%3.78MMar 31, 2026
Venrock Healthcare Capital Partners III, L.P.6.00%3.6MFeb 9, 2026
BlackRock, Inc.5.10%3.14MJun 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Peter Harwin
Other companies: Alaunos Therapeutics, Inc. (Founding Partner, Fairmount Funds Management LLC · Since at least Oct 13, 2026); Crescent Biopharma, Inc. (Chair of Board · Since at least Jun 13, 2025); Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); Spyre Therapeutics, Inc. (Director · Since at least Jun 22, 2023); Cogent Biosciences, Inc. (Founding Partner, Fairmount Funds Management LLC · Since at least Jul 6, 2020); Dianthus Therapeutics, Inc. (Director · Sep 11, 2023 – Jan 22, 2024 · Past); Viridian Therapeutics, Inc. (Director · Oct 27, 2020 – Jun 26, 2024 · Past)
Chairman of the Board · Since at least Nov 10, 2025
Jennifer Jarrett
Other companies: Sagimet Biosciences Inc. - Series A (Board Member · Since at least Aug 1, 2024); Zura Bio Limited (Director · Since at least Mar 20, 2023); Syndax Pharmaceuticals, Inc. (Director · Since at least Sep 25, 2018); Arcus Biosciences, Inc. (Chief Operating Officer · Since at least Mar 14, 2018); Radius Health, Inc. (Director · May 18, 2022 – Aug 15, 2022 · Past); Surrozen, Inc. (Director · Nov 18, 2020 – Nov 18, 2020 · Past); Arena Pharmaceuticals Inc (Director · Jun 13, 2017 – Mar 11, 2022 · Past); Audentes Therapeutics Inc (Director · Jun 12, 2017 – Jan 15, 2020 · Past); Medivation Inc (Chief Financial Officer · Apr 7, 2016 – Sep 28, 2016 · Past)
President and Chief Executive Officer in March 2026, Board Director · Since at least Mar 30, 2026
Amit Munshi
Other companies: Arcutis Biotherapeutics, Inc. (Director · Since at least Dec 4, 2025); Inhibikase Therapeutics, Inc. (Board of Directors Chair, Inhibikase; Chief Executive Officer of Orna Therapeutics · Since at least Oct 21, 2024); Zura Bio Limited (Chairman · Since at least Mar 20, 2023); Social Capital Suvretta Holdings Corp IV (Director · Jun 29, 2021 – Jun 29, 2021 · Past); Pulmatrix, Inc. (Director · Jun 13, 2017 – Jan 28, 2021 · Past); Arena Pharmaceuticals Inc (President and CEO, Director · May 11, 2016 – Mar 11, 2022 · Past); EPIRUS Biopharmaceuticals Inc (Chief Executive Officer, Director · Jul 15, 2014 – Feb 27, 2016 · Past)
Director · Since at least Oct 28, 2020
Chau Quang Khuong
Other companies: Fusion Pharmaceuticals Inc (Director · Jun 25, 2020 – Jun 14, 2023 · Past); Whitehawk Therapeutics, Inc. (Director · Jun 18, 2019 – Jun 18, 2019 · Past); Synlogic Inc (Director · Jun 5, 2019 – Apr 20, 2021 · Past); NextCure, Inc. (Director · May 8, 2019 – Jun 22, 2023 · Past); Inspire Medical Systems, Inc. (Director · Apr 10, 2019 – Oct 9, 2020 · Past)
Director · Oct 28, 2020 – Jun 14, 2023 · Past
Andrew Cheng
Other companies: TCGX Acquisition Corp. (Director · Since at least Aug 4, 2026); Vera Therapeutics, Inc. (Director · Since at least May 13, 2021); Akero Therapeutics Inc (President and CEO, Director · Since at least Jun 19, 2019); Arbutus Biopharma Corporation (Director · Aug 17, 2019 – Jun 3, 2021 · Past)
Board Director · Since at least Aug 10, 2026
Cameron Turtle
Other companies: Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Spyre Therapeutics, Inc. (Chief Executive Officer · Since at least Jun 22, 2023); BridgeBio Pharma, Inc. (See Remarks · Jun 27, 2019 – Dec 28, 2020 · Past); Eidos Therapeutics Inc (Chief Business Officer · Nov 5, 2018 – Jan 26, 2021 · Past)
Board Director · Since at least Mar 23, 2026
Carl Goldfischer
Other companies: Enliven Therapeutics, Inc. (Director · Mar 11, 2020 – Jun 2, 2022 · Past); Epizyme Inc (Director · May 30, 2013 – Aug 12, 2022 · Past); Zvue Corp (Director · Oct 1, 2008 – Oct 1, 2008 · Past); ReShape Lifesciences Inc (Director · Nov 14, 2007 – May 25, 2017 · Past)
Director · Since at least Oct 28, 2020
Anne Prener
Other companies: Keros Therapeutics, Inc. (Director · Since at least Jun 25, 2026); Kaleido Biosciences, Inc. (Director · Apr 1, 2020 – Jun 30, 2021 · Past); Rubius Therapeutics Inc (Director · Dec 17, 2019 – May 12, 2022 · Past)
Director · Since at least Jan 8, 2021
Chris Cain
Other companies: Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Viridian Therapeutics, Inc. (Director · Since at least Mar 10, 2025); Cogent Biosciences, Inc. (Director · Since at least Jul 6, 2020)
Board Director · Since at least Nov 10, 2025
David Shapiro
Other companies: Design Therapeutics, Inc. (Director · Since at least Mar 31, 2026); VivoSim Labs, Inc. (Director · Dec 4, 2018 – Sep 5, 2019 · Past); Intercept Pharmaceuticals Inc (Chief Medical Officer · Oct 10, 2012 – May 1, 2019 · Past)
Director · Since at least Oct 28, 2020
All 28 people
PersonSeat
Jayson Donald Alexander Dallas
Other companies: Aimmune Therapeutics Inc (President and CEO, Director · Jun 19, 2018 – Oct 10, 2020 · Past); Arena Pharmaceuticals Inc (Director · Feb 13, 2017 – Mar 11, 2022 · Past); Ultragenyx Pharmaceutical Inc. (EVP & Chief Commercial Officer · Aug 3, 2015 – Jun 1, 2018 · Past)
Director · Since at least Nov 19, 2020
Amy B. Wechsler
Other companies: Bausch Health Companies Inc. (Board-Certified Dermatologist & Psychiatrist, Dr. Amy Wechsler Dermatology · Since at least Jun 14, 2016)
Director · Since at least Oct 11, 2024
Becker Hewes
Other companies: Blueprint Medicines Corp (Chief Medical Officer · Since at least Jan 11, 2021)
Chief Medical Officer · Since at least Jan 5, 2026
Brian Burkavage
Other companies: Passage Bio, Inc. (Controller · May 30, 2021 – May 30, 2021 · Past)
Senior Vice President, Finance · Since at least May 1, 2026
Garrett Winslow
Other companies: Spring Bank Pharmaceuticals Inc (General Counsel and Secretary · Mar 5, 2020 – Mar 5, 2020 · Past)
General Counsel · Since at least May 3, 2021
Jonathan Freve
Other companies: Spring Bank Pharmaceuticals Inc (CFO & Treasurer · May 5, 2016 – Mar 5, 2020 · Past)
Chief Financial Officer · Oct 28, 2020 – Jan 3, 2024 · Past
Julianne Bruno
Other companies: CRISPR Therapeutics AG (Chief Operating Officer · May 23, 2024 – Mar 20, 2025 · Past)
Board Director · Since at least Nov 10, 2025
Lori Firmani
Other companies: Spring Bank Pharmaceuticals Inc (VP of Finance and Treasurer · Apr 24, 2020 – Apr 24, 2020 · Past)
Chief Financial Officer · Since at least Aug 12, 2024
Michael Landsittel
Other companies: Blueprint Medicines Corp (Chief Financial Officer · Since at least Aug 11, 2015)
Board Director · Since at least Mar 23, 2026
Anders PedersenChief Operating Officer · Oct 28, 2020 – Jan 4, 2023 · Past
Bertil LindmarkChief Medical Officer · Oct 28, 2020 – Jan 4, 2023 · Past
Hans T SchambyeChief Executive Officer, Director · Since at least Oct 28, 2020
Jim BakerChief Corporate Affairs Officer · Since at least Oct 5, 2026
Matthew KronmillerEVP Strategy and CBO · Oct 7, 2024 – Jan 3, 2025 · Past
Sherwin SattarzadehChief Operating Officer · Since at least Jan 5, 2026
Soren MollerDirector · Oct 28, 2020 – Oct 28, 2020 · Past
Stephan ChristgauDirector · Oct 28, 2020 – Nov 2, 2020 · Past
Stephanie OestreichChief Business Officer · Jan 5, 2022 – Jan 4, 2023 · Past

Open People

Log in to ask 6ix AI your own questions about Damora Therapeutics, Inc.